In vitro evaluation of the growth inhibition and apoptosis effect of mifepristone (RU486) in human Ishikawa and HEC1A endometrial cancer cell lines

Cancer Chemotherapy and Pharmacology

Volumn 62, Issue 3, 2008, Pages 483-489

  Navo, Marisa A ^a   Smith, Judith A ^a,b   Gaikwad, Anjali ^a   Burke, Thomas ^a   Brown, Jubilee ^a   Ramondetta, Lois M ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Cancer; Endometrial; Estrogen receptor; Mifepristone; Progesterone; RU486

Indexed keywords

CYCLOOXYGENASE 2; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; MIFEPRISTONE; PROGESTERONE RECEPTOR; PROGESTERONE RECEPTOR ALPHA; PROGESTERONE RECEPTOR BETA; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

APOPTOSIS; ARTICLE; BIOACCUMULATION; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG ACCUMULATION; DRUG EFFECT; DRUG MECHANISM; ENDOMETRIUM CANCER; FEMALE; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; NITROBLUE TETRAZOLIUM TEST; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT DURATION;

APOPTOSIS; CELL LINE, TUMOR; CYCLOOXYGENASE 2; ENDOMETRIAL NEOPLASMS; FEMALE; FLOW CYTOMETRY; HORMONE ANTAGONISTS; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITORY CONCENTRATION 50; MIFEPRISTONE; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, STEROID; TUMOR SUPPRESSOR PROTEIN P53;

EID: 45849123245     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0628-z     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E et al (2007) Cancer statistics, 2006. CA Cancer J Clin 57:43-66
2. Ellenson LH, Wu TC (2004) Focus on endometrial and cervical cancer. Cancer Cell 5:533-538
3. Humber C, Tierney J, Symonds P et al (2005) Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma. Cochrane Database Syst Rev (4):CD003915
4. Kaaks R, Lukanova A, Kurzer MS (2002) Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev 11:1531-1543
5. Gadducci A, Gargini A, Palla E, Fanuchhi A, Genazzani AR (2005) Polycystic ovary syndrome and gynecological cancers: is there a link? Gynecol Endocrinol 20:200-208
6. Danco Laboratories LLC (2005) Mifeprex (mifepristone) package insert. New York
7. Spitz IM (2003) Progesterone antagonists and progesterone receptor modulators: an overview. Steroids 68:981-993
8. Spitz IM, Robbins A (1998) Mechanism of action and clinical effects of antiprogestins on the non-pregnant uterus. Hum Reprod Update 4:584-593
9. Steinauer J, Pritts EA, Jackson R, Jacoby AF (2004) Systematic review of mifepristone for the treatment of uterine leiomyomata. Obstet Gynecol 103:1331-1336
10. Fiscella K, Eisinger SH, Meldrum S, Feng C, Fisher SG, Guzick DS (2006) Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size. Obstet Gynecol 108:1381-1387
11. Mahajan DK, London SN (1997) Mifepristone (RU486): a review. Fertil Steril 68:967-976
12. Eisinger SH, Meldrum S, Fiscella K, le Roux HD, Guzick DS (2003) Low-dose mifepristone for uterine leiomyomata. Obstet Gynecol 101:243-250
13. Han S, Sidell N (2003) RU486-induced growth inhibition of human endometrial cells involves the nuclear factor-kappa B signaling pathway. J Clin Endocrinol Metab 88:713-719
14. Jiang J, Wu R, Wang Z, Sun H, Xu Z, Xiu H (2002) Effect of mifepristone on estrogen and progesterone receptors in human endometrial and endometriotic cells in vitro. Fertil Steril 77:995-1000
15. Li A, Felix JC, Minoo P, Amezcua CA, Jain JK (2005) Effect of mifepristone on proliferation and apoptosis of Ishikawa endometrial adenocarcinoma cells. Fertil Steril 84:202-211
16. Schneider CC, Gibb RK, Taylor DD, Wan T, Gercel-Taylor C (1998) Inhibition of endometrial cancer cell lines by mifepristone (RU486). J Soc Gynecol Invest 5:334-338
17. Mirkin S, Archer DF (2004) Effects of mifepristone on vascular endothelial growth factor and thrombospondin-1 mRNA in Ishikawa cells: implication for the endometrial effects of mifepristone. Contraception 70:327-333
18. Kamradt MC, Mohideen N, Vaughan AT (2000) RU486 increases radiosensitivity and restores apoptosis through modulation of HPV E6/E7 in dexamethasone-treated cervical carcinoma cells. Gynecol Oncol 77:177-182
19. Smith JA, Gaikwad A, Ramondetta LM, Wolf JK, Brown J (2006) Determination of the mechanism of gemcitabine modulation of cisplatin drug resistance in panel of human endometrial cancer cell lines. Gynecol Oncol 103:518-522
20. Murphy AA, Zhou MH, Malkapuram S, Santanam N, Parthasarathy S, Sidell N (2000) RU486-induced growth inhibition of human endometrial cells. Fertil Steril 74:1014-1019
21. Liang Y, Hou M, Kallab AM, Barrett JT, El Etreby F, Schoenlein PV (2003) Induction of antiproliferation and apoptosis in estrogen receptor negative MDA-231 human breast cancer cells by mifepristone and 4-hydroxytamoxifen combination therapy: a role for TGFbeta1. Int J Oncol 23:369-380
22. Lin VC-L, Aw SE, Ng EG, Ng EH-L, Tan MG-K (2001) Demonstration of mixed properties of RU486 in progesterone receptor (PR)-transfected MDA-MB-231 cells: a model for studying the functions of progesterone analogues. Br J Cancer 85:1978-1986
23. Gaddy VT, Barrett JT, Delk JN, Kallab AM, Porter AG, Schoenlein (2004) Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestrogen-resistant breast cancer cells. Clin Cancer Res 10:5215-5225
24. Lessey BA, Ilesanmi AO, Castelbaum AJ et al (1996) Characterization of the functional progesterone receptor in an endometrial adenocarcinoma cell line (Ishikawa): progesterone-induced expression of the α1 integrin. Steroid Biochem Molec Biol 59:31-39
25. Bertagna X, Bertagna C, Luton JP, Husson JM, Girard F (1984) The new steroid analog RU 486 inhibits glucocorticoid action in man. J Clin Endocrinol Metab 59:25-28
26. Rae MT, Niven D, Critchley H, Harlow CR, Hillier SG (2004) Antiinflammatory steroid action in human ovarian surface epithelial cells. J Clin Endocrinol Metab 89:4538-4544
27. Chivers JE, Cambridge LM, Catley MC et al (2004) Differential effects of RU486 reveal distinct mechanisms for glucocorticoid repression of prostaglandin E release. Eur J Biochem 271:4042-4052
28. Rose FV, Barnea ER (1996) Response of human ovarian carcinoma cell lines to antiprogestin mifepristone. Oncogen 12:999-1003
29. Sun Y (2006) p53 and its downstream proteins as molecular targets of cancer. Mol Carcinog 45:409-415
30. Skildum A, Faivre E, Lange CA (2005) Progesterone receptors induce cell cycle progression via activation of mitogen-activated protein kinases. Mol Endocrinol 19:327-329